What it is
Enfuvirtide is a 36-amino-acid synthetic peptide that stops HIV-1 from merging with a human cell. PubChem lists it residue by residue — N-acetyl-tyrosine through to a C-terminal phenylalaninamide — with the formula C204H301N51O64 and a molecular weight of about 4,492. It was developed as T-20 and sold from 2003 as Fuzeon, the first drug of the class called fusion inhibitors.
| Property | Value | Source |
|---|---|---|
| Length | 36 amino acids | PubChem description |
| Formula | C204H301N51O64 | PubChem CID 16130199 |
| Molecular weight | 4,492 | PubChem |
| Ends | N-acetyl; C-terminal amide | PubChem |
| Route | Subcutaneous, twice daily | TORO 1 and TORO 2 |
How it acts. HIV-1 enters a cell by fusing its outer envelope with the cell membrane. The trial reports describe enfuvirtide as "a novel antiretroviral that blocks HIV-1 cell fusion and viral entry" (Lalezari 2003, Antivir Ther). Because it works at that first step, outside the cell, its activity did not depend on the enzymes that the older drug classes target — which is why it was tested in people whose virus resisted all three of those classes.
Other peptides in the library that act against microbes, such as the body's own defensins and the antibiotic daptomycin, are not HIV drugs; enfuvirtide is the library's only fusion inhibitor.
What the trials showed
Two randomised, open-label phase 3 trials ran in parallel. Both enrolled people with at least 5,000 copies of HIV-1 RNA per millilitre who had been treated with, or were resistant to, three classes of antiretroviral drugs, and both randomised 2:1 to enfuvirtide 90 mg twice daily plus an optimised background regimen, or the regimen alone.
| 24-week result | TORO 1 (Americas) | TORO 2 (Europe, Australia) |
|---|---|---|
| Patients randomised | 501 | 512 |
| Median baseline viral load | 5.2 log10 copies/mL | 5.1 log10 copies/mL |
| Median baseline CD4+ (enfuvirtide / control) | 75.5 / 87.0 cells/mm³ | 98.0 / 101.5 cells/mm³ |
| Viral-load change, enfuvirtide | −1.696 log10 | −1.429 log10 |
| Viral-load change, control | −0.764 log10 | −0.648 log10 |
| CD4+ change (enfuvirtide / control) | +76 / +32 | +65.5 / +38.0 |
Both differences in viral load were significant (P < 0.001), and so were the CD4+ differences (P < 0.001 in TORO 1, P = 0.02 in TORO 2). A difference of 0.8 log10 means the viral load ended roughly six times lower than with the background regimen alone (10^0.8 ≈ 6.3). These patients had very low CD4+ counts at baseline — a population with few remaining options.
What is not established by these trials: any benefit in people new to treatment (the TORO trials enrolled only heavily treated patients), and outcomes beyond the 24-week primary analysis reported in these abstracts.
Risks the trials recorded
- Injection-site reactions: reported by 98% of enfuvirtide patients in TORO 1; in a 48-week phase 2 study they occurred at least once in 68.5% of enfuvirtide-treated patients, mostly mild to moderate (PMID 14518696).
- Pneumonia: TORO 1 recorded more cases of pneumonia with enfuvirtide than in the control group.
- Burden: two subcutaneous injections a day on top of an oral regimen. A pharmacokinetic study found absorption comparable from abdomen, thigh and arm (relative bioavailability 101% and 117% against the abdomen), so sites could be rotated (PMID 12957192).
Where it stands
Drugs@FDA records Fuzeon under NDA 021481, held by Roche, with original approval on 13 March 2003 under priority review, and on 2026-11-20 listed the product as discontinued. Neither openFDA nor DailyMed held a current Fuzeon label that day, so this entry reports trial doses rather than label text, and does not state why or when sales ended. PubMed holds 1,076 records for enfuvirtide and ClinicalTrials.gov 54 studies.
Sources opened 2026-11-20: PubChem CID 16130199 (properties and description); Drugs@FDA record for NDA 021481; openFDA and DailyMed searches for a Fuzeon label (none current); Lalezari 2003, NEJM (TORO 1, PMID 12637625, abstract); Lazzarin 2003, NEJM (TORO 2, PMID 12773645, abstract); Lalezari 2003, Antivir Ther (PMID 14518696, abstract); Lalezari 2003, J Clin Virol (PMID 12957192, abstract); Lalezari 2003, AIDS Read (PMID 12765160, abstract); PubMed E-utilities and ClinicalTrials.gov API v2 counts.
